Right now the FDA is in the middle of approving a whole new class of vaccines and that's the RSV vaccine.

And if you remember we reported on this just a couple of years ago there was an RSV as a respiratory

sensitional virus. It usually comes during the winter time. It's a respiratory virus and it was

coming off season. So the people with the COVID shots were out and people were locked down and you

have this you had this virus that was spreading in the summer instead of during the winter where

it usually spreads. Here's the headlines from that time. Why the respiratory disease RSV is

having an off season surge. One of the first in several years and people were saying well you

know it's the immunity gap. People were locked down. They didn't develop the immunity against this

and then when we were you know when the lockdowns were released in certain areas then people

were just getting this but they noticed that other diseases, respiratory disease like the flu

were not surging. So people were kind of scratching their head but no one in the media except us really

was reporting on the fact that in modernist COVID trials from the six-year-old to six-month-old

to five-year-olds we're having increased RSV cases when they were in these trials compared to the

placebo arms. No one talked about that. So now we fast forward to current currently this month.

60 and up was approved. So FDA approves world's first RSV vaccine a shot for adults ages 60 and up

and that brings us to this headline. Vaccinating this is their next kind of venture. Vaccinating

pregnant women against RSV helps prevent severe illness and newborns study shows. This is a

Matisse trial. This was fully funded by Pfizer and then published in the New England Journal of Medicine.

The FDA, the Verpat committee spoke about this. This is their by-valent protein-based vaccine

and we go into the article here to talk about this and the article is kind of just like a press release

from Pfizer. There were no major safety concerns with the vaccine. Although 5.6% of pregnancies in

the vaccine group ended in premature delivery compared to 4.7% in the placebo group. That's kind

...